Human Epilepsy Project 2: Resistant Focal Seizures Study
Completed
Conditions studied: Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Biomarkers
In brief
The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in health status, healthcare costs, quality of life, and biomarkers of epilepsy severity and treatment response.
Key facts
- Study ID
- NCT03531008
- Run by
- Epilepsy Foundation of America
- People needed
- 157
- Starts
- 2018-05-07
- Expected to finish
- 2022-09-30
- Last updated by the study team
- 2023-09-18
Who can join
Age: 16 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 16 years and ≤ 65 years at time of enrollment
- Diagnosed with focal epilepsy with prior vEEG confirmation; if no VEEG confirmation, but in the opinion of the investigator the seizures are definite, the case can be reviewed and adjudicated by the consortium
- Failure of adequate trials of 4 AEDs, with at least 2 due to failure of seizure control, including current AEDs
- Have a seizure frequency of ≥ 2 focal seizures/month, including auras, and at least 1 observable seizures/month, that are countable by the subject and/or caregiver for the 3 months prior to enrollment
- Able to keep a daily seizure diary, either independently or with assistance from a caregiver
- Able to retrospectively report number of seizures/month for 3 months prior to enrollment
- Receiving ≥ 1 AED for treatment of seizures
You may not qualify if…
- Patient has a diagnosis of idiopathic ("primary") generalized epilepsy (e.g., juvenile myoclonic epilepsy, absence epilepsy) or mixed focal and generalized (e.g., Lennox-Gastaut syndrome) or non-epileptic seizures within the last 12 months prior to study entry
- Progressive medical or neurological disorder (brain tumor, AD, PME, etc.)
- Proven autoimmune etiology
- Planning pregnancy in the next 12 months
- Has completed a pre-surgical evaluation and intends to pursue surgery in the near term
- Resective surgery and/or RNS/VNS in place less than 12 months prior to enrollment
- Presence of moderate or greater developmental or cognitive delay (e.g., if an adolescent, not in self-contained classroom; if IQ is documented, should be ≥ 70)
- History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years
- Medical, psychiatric or psychosocial condition that would be expected to interfere with the conduct of the study
- Enrolled in any interventional study that required a blinded portion or involves a non-FDA approved drug or device
Where it is running
- University of California San Francisco — San Francisco, California, United States
- Yale Comprehensive Epilepsy Center — New Haven, Connecticut, United States
- University of Miami — Miami, Florida, United States
- Idaho Comprehensive Epilepsy Center — Boise, Idaho, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Minnesota Epilepsy Group — Saint Paul, Minnesota, United States
- New York University — New York, New York, United States
- Northwell Health Comprehensive Epilepsy Center — New York, New York, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Vanderbilt Epilepsy Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.